Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 42 of 509 for:    ASPIRIN AND P2

Walking Effect of Long Term Ticagrelor in Subjects With PAD Who Have Undergone EVR (TI-PAD EVR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02227368
Recruitment Status : Terminated
First Posted : August 28, 2014
Results First Posted : June 14, 2017
Last Update Posted : July 19, 2017
Sponsor:
Collaborator:
CPC Clinical Research
Information provided by (Responsible Party):
AstraZeneca

Brief Summary:
To compare the effect of ticagrelor versus aspirin on the change in peak walking time, evaluated on the graded treadmill test, from one to 26 weeks post-revascularization in patients with peripheral artery disease who have undergone endovascular revascularization for moderate to severe claudication or ischemic rest pain.

Condition or disease Intervention/treatment Phase
Peripheral Artery Disease (PAD) Drug: Ticagrelor Drug: Comparator Phase 2

Detailed Description:
A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients with Peripheral Artery Disease Undergoing Endovascular Revascularization - The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II Multicentre, Randomised, Double-Blind, Controlled, Parallel-Group Study to Evaluate the Walking Time Effect of Long-Term Ticagrelor in Comparison to Long-Term Aspirin Administration in Ambulatory Patients With Peripheral Artery Disease Undergoing Endovascular Revascularization - The Ticagrelor in Peripheral Artery Disease Endovascular Revascularization Study TI-PAD I EVR
Actual Study Start Date : October 20, 2014
Actual Primary Completion Date : May 23, 2016
Actual Study Completion Date : May 23, 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Ticagrelor
26 Weeks of ticagrelor 90mg twice a day plus aspirin placebo once daily
Drug: Ticagrelor
Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
Other Name: Brilinta

Active Comparator: Aspirin
26 Weeks of aspirin 100mg once daily plus ticagrelor placebo twice a day
Drug: Comparator
Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures
Other Name: Aspirin




Primary Outcome Measures :
  1. Change From Baseline in Log Transformed Peak Walking Time (PWT) at Week 26 or Early Termination (ET) [ Time Frame: 26 Weeks ]

Secondary Outcome Measures :
  1. Change From Baseline in Log Transformed Claudication Onset Time (COT) at Week 26 or Early Termination (ET) [ Time Frame: 26 Weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 130 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. Written informed consent prior to any study specific procedures.
  2. Ambulatory male or female outpatients aged 50 years of age or older at the time of the Screening Visit.
  3. EVR, below the inguinal ligament that includes the distal SFA and/or popliteal and/or tibial arteries, that is planned to occur within 5 weeks after the Screening Visit, as determined and clearly documented by the Principal Investigator or physician Sub-Investigator (MD/DO). Patients undergoing a proximal revascularization may be enrolled as long as their procedure also includes treating the distal SFA, popliteal or tibial arteries. The EVR must be confirmed as technically successful (a completed procedure where haemostasis has been achieved) before the patient is randomised.
  4. Normal inflow into the lower extremity as determined by the Principal Investigator or physician Sub-Investigator (MD/DO). Adequacy of inflow can be assessed by hemodynamic measures, angiography or other imaging modalities obtained during Screening or recorded in the medical records up to 30 days prior to the Screening Visit or as defined by imaging at the time of the procedure. A patient with inadequate inflow at the time of Screening can still be enrolled if the inflow is addressed and resolved by the planned revascularization procedure.
  5. Diagnosis of PAD confirmed by history and any one of the following observed in the index (intervention) leg at the Screening Visit:

    1. Resting ABI ≤0.90, or
    2. In patients with an ABI > 1.40 (non-compressible vessels) a resting GTI <0.70 can be used for inclusions.
  6. Patient has been advised of the beneficial effects of smoking cessation and exercise therapy but is not in the process of changing their smoking status or exercise at the time of the Screening Visit.

Exclusion Criteria

  1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
  2. Revascularisation planned only to treat proximal (inflow) disease in the iliac and/or common femoral arteries.
  3. Previous randomisation in the present study.
  4. Participation in another clinical study with an investigational product within the last 3 months or any new clinical trial during the course of this study.
  5. Gangrene or ischemic ulcer of either lower extremity.
  6. PAD of a non-atherosclerotic nature.
  7. Clinical necessity to use dual antiplatelet therapy within 7 days prior to randomisation, or single anti-platelet therapy (ticlopidine, prasugrel, vorapaxar, ticagrelor or dipyridamole) other than clopidogrel or aspirin. Clopidogrel or aspirin can be taken up to and including the time that the loading dose is being given.
  8. Clinical necessity to use the following restricted concomitant medications within 4 weeks prior to randomisation. Patients taking any of these medications at the Screening Visit may be considered for randomisation after a 4 week washout period from the medication.

    1. Pentoxifylline or cilostazol for relief of claudication symptoms
    2. Chronic oral or parenteral anticoagulant therapy (greater than 7 days)
    3. Strong inhibitors of CYP3A enzymes (Section 5.6.9.1)
    4. Strong inducers of CYP3A enzymes (Section 5.6.9.2)
    5. Simvastatin or lovastatin at daily doses over 40 mg
  9. Any disease process (e.g. angina, cardiac abnormality, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), respiratory disease, obesity, stroke, severe neuropathy of the foot, symptomatic musculoskeletal disease of the lower extremity), other than PAD, that would interfere with exercise performance during the ETT or prevent the patient from reaching their claudication-limited PWT as the primary endpoint of the study.
  10. Coronary, aortic surgery, angioplasty, lumbar sympathectomy or lower extremity surgery that impacts the ability to walk on a treadmill within the past 3 months prior to EVR. Revascularization of the non-index lower extremity within the past 4 weeks prior to EVR.
  11. Any major lower limb amputation due to PAD anticipated within the next 3 months or prior major amputation due to PAD (minor toe amputations allowed if it does not interfere with ambulation).
  12. Myocardial infarction or stroke in the previous 3 months.
  13. Any concomitant disease process with a life expectancy of less than 1 year or which is sufficiently severe as to compromise the validity of test performance.
  14. Dementia likely to jeopardise understanding of information pertinent to study conduct or compliance to study procedures.
  15. Concern for the inability of the patient to comply with study procedures and/or followup (e.g., alcohol or drug abuse).
  16. Resting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥95 mmHg at the Screening Visit, in spite of antihypertensive treatments allowed by the protocol.
  17. A known bleeding diathesis, haemostatic or coagulation disorder, or systemic bleeding, whether resolved or ongoing.
  18. Known severe liver disease (e.g., ascites and or clinical signs of coagulopathy).
  19. Renal failure requiring dialysis.
  20. History of previous intracranial bleed at any time, gastrointestinal bleed within the past 6 months, or major surgery within 30 days (if the surgical wound is judged to be associated with an increased risk of bleeding).
  21. History of thrombocytopenia or neutropenia.
  22. Hypersensitivity to ticagrelor, aspirin or lactose.
  23. Initiation of antidiabetic, antihypertensive, lipid-lowering and beta-blocking drugs within 1 month prior to the Screening Visit.
  24. Pregnancy, lactation, fertility without protection against pregnancy (for women of childbearing potential; a urine or serum pregnancy test will be performed at the Screening Visit).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02227368


Locations
Layout table for location information
United States, Florida
Research Site
Daytona Beach, Florida, United States, 32114
Research Site
Jacksonville, Florida, United States, 32216
Research Site
Ocala, Florida, United States, 34471
Research Site
Sarasota, Florida, United States, 34239
United States, Indiana
Research Site
Munster, Indiana, United States, 46321
United States, New York
Research Site
New York, New York, United States, 10001
Research Site
Yonkers, New York, United States, 10701
United States, Ohio
Research Site
Cleveland, Ohio, United States, 44195
United States, Texas
Research Site
McKinney, Texas, United States, 75069
Research Site
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
AstraZeneca
CPC Clinical Research
Investigators
Layout table for investigator information
Principal Investigator: William Hiatt, MD Colorado Prevention Center Clinical Research

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02227368     History of Changes
Other Study ID Numbers: D5135L00003
First Posted: August 28, 2014    Key Record Dates
Results First Posted: June 14, 2017
Last Update Posted: July 19, 2017
Last Verified: June 2017
Keywords provided by AstraZeneca:
Purinegic P2Y Receptor Antagonists
Purinegic P2 Receptor Antagonists
Myocardial Infarction
Peripheral Arterial disease
Mycardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Altherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Peripheral Vascular Diseases
Ticagrelor
Ticlopidine
Platelet Aggregation inhibitors
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Actions
Physiological Effects of Drugs
Fibrinolytic Agents
Crardiovascular Agents
Additional relevant MeSH terms:
Layout table for MeSH terms
Aspirin
Purinergic P2Y Receptor Antagonists
Purinergic P2 Receptor Antagonists
Peripheral Arterial Disease
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Peripheral Vascular Diseases
Ticagrelor
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents
Antirheumatic Agents
Fibrinolytic Agents
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Antipyretics
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents